Uni-Bio Science Group Limited (0690.HK) HKSE

0.09

+0(+0.00%)

Updated at June 03 04:08PM

Currency In HKD

Uni-Bio Science Group Limited

Address

No. 20 Science Park East Avenue

Sha Tin,

Hong Kong

Phone

852 3102 3232

Sector

Healthcare

Industry

Biotechnology

Employees

487

First IPO Date

November 12, 2001

Key Executives

NameTitlePayYear Born
Zhi Gang ZhaoChief Executive Officer & Executive Director1.51M1965
Dawei Chen EMBAExecutive Vice Chairman of the Board378,0001970
Ya Lei WenChief Operating Officer & Executive Director1.72M1961
Kingsley Leung AHKIoDExecutive Chairman of the Board3.16M1987
Shan YuHead of R&D0N/A
Wen Du AnHead of Distribution Sales01983
Wei TianHead of HR & Administration Department01984
Kai DuHead of Financial & Financial Controller01981
Wenming ChenHead of the Medical & Registration Department01987
Jing LiHead of R&D Department01980
Yujing HongHead of Strategic Development & Emerging Business0N/A

Description

Uni-Bio Science Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of biological and chemical pharmaceutical products to treat human diseases in the People's Republic of China. The company provides GeneTime, a prescription biological drug for wound healing; GeneSoft, an EGF eye drop for dry eye syndrome, corneal damage, and post-operative healing; Pinup, a voriconazole tablet to treat severe fungal infections; and Bokangtai, a mitiglinide tablet for the treatment of Type 2 diabetes, as well as Boshutai, an oral anti-diabetic drug targeting patients with pre-diabetes condition. It is also developing prescription drugs, including rExendin-4 (Uni-E4) for Type 2 diabetes; and rhPTH 1-34 (Uni-PTH) for the treatment of osteoporosis in postmenopausal women, as well as Uni-GLP, a GLP-1 agonist, a non-insulin treatment candidate for the treatment of Type 2 diabetes. The company was founded in 2001 and is headquartered in Sha Tin, Hong Kong.